# Hydralazine Valproate for Ovarian Cancer

> **NCT00533299** · PHASE3 · UNKNOWN · sponsor: **National Institute of Cancerología** · enrollment: 211 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Hydralazine and magnesium valproate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00533299
- **Lead sponsor:** National Institute of Cancerología
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** —
- **Final completion:** 2009-12
- **Target enrollment:** 211 (ESTIMATED)
- **Last updated:** 2007-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00533299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00533299, "Hydralazine Valproate for Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00533299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*